Purple Market Capitalization from 2010 to 2024
| PPBT Stock | USD 6.57 1.83 21.79% |
Check Purple Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Purple Biotech's main balance sheet or income statement drivers, such as Depreciation And Amortization of 208.9 K, Interest Expense of 2.3 M or Selling General Administrative of 4.6 M, as well as many indicators such as Price To Sales Ratio of 84.89, Dividend Yield of 0.088 or PTB Ratio of 0.49. Purple financial statements analysis is a perfect complement when working with Purple Biotech Valuation or Volatility modules.
Purple | Market Capitalization |
Latest Purple Biotech's Market Capitalization Growth Pattern
Below is the plot of the Market Cap of Purple Biotech over the last few years. It is Purple Biotech's Market Cap historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Purple Biotech's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 13.16 M | 10 Years Trend |
|
Market Cap |
| Timeline |
Purple Market Capitalization Regression Statistics
| Arithmetic Mean | 17,574,647 | |
| Geometric Mean | 11,053,698 | |
| Coefficient Of Variation | 102.15 | |
| Mean Deviation | 12,371,841 | |
| Median | 14,268,888 | |
| Standard Deviation | 17,952,121 | |
| Sample Variance | 322.3T | |
| Range | 65.8M | |
| R-Value | 0.60 | |
| Mean Square Error | 221.6T | |
| R-Squared | 0.36 | |
| Significance | 0.02 | |
| Slope | 2,413,120 | |
| Total Sum of Squares | 4511.9T |
Purple Market Capitalization History
About Purple Biotech Financial Statements
Purple Biotech shareholders use historical fundamental indicators, such as Market Capitalization, to determine how well the company is positioned to perform in the future. Although Purple Biotech investors may analyze each financial statement separately, they are all interrelated. The changes in Purple Biotech's assets and liabilities, for example, are also reflected in the revenues and expenses on on Purple Biotech's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. Purple Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 19 people.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Purple Stock Analysis
When running Purple Biotech's price analysis, check to measure Purple Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Purple Biotech is operating at the current time. Most of Purple Biotech's value examination focuses on studying past and present price action to predict the probability of Purple Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Purple Biotech's price. Additionally, you may evaluate how the addition of Purple Biotech to your portfolios can decrease your overall portfolio volatility.